Logo image of ORKA

ORUKA THERAPEUTICS INC (ORKA) Stock Fundamental Analysis

NASDAQ:ORKA - Nasdaq - US6876041087 - Common Stock - Currency: USD

14.21  +0.51 (+3.72%)

After market: 14.21 0 (0%)

Fundamental Rating

3

ORKA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ORKA has a great financial health rating, but its profitability evaluates not so good. ORKA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ORKA had negative earnings in the past year.
ORKA had a negative operating cash flow in the past year.
In the past 5 years ORKA always reported negative net income.
ORKA had a negative operating cash flow in each of the past 5 years.
ORKA Yearly Net Income VS EBIT VS OCF VS FCFORKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.27%, ORKA is in the better half of the industry, outperforming 76.28% of the companies in the same industry.
The Return On Equity of ORKA (-22.10%) is better than 84.07% of its industry peers.
Industry RankSector Rank
ROA -21.27%
ROE -22.1%
ROIC N/A
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ORKA Yearly ROA, ROE, ROICORKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

ORKA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORKA Yearly Profit, Operating, Gross MarginsORKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

ORKA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ORKA has been increased compared to 5 years ago.
There is no outstanding debt for ORKA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORKA Yearly Shares OutstandingORKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
ORKA Yearly Total Debt VS Total AssetsORKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 218.62 indicates that ORKA is not in any danger for bankruptcy at the moment.
The Altman-Z score of ORKA (218.62) is better than 99.65% of its industry peers.
There is no outstanding debt for ORKA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 218.62
ROIC/WACCN/A
WACCN/A
ORKA Yearly LT Debt VS Equity VS FCFORKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 26.61 indicates that ORKA has no problem at all paying its short term obligations.
The Current ratio of ORKA (26.61) is better than 96.99% of its industry peers.
ORKA has a Quick Ratio of 26.61. This indicates that ORKA is financially healthy and has no problem in meeting its short term obligations.
ORKA has a Quick ratio of 26.61. This is amongst the best in the industry. ORKA outperforms 96.99% of its industry peers.
Industry RankSector Rank
Current Ratio 26.61
Quick Ratio 26.61
ORKA Yearly Current Assets VS Current LiabilitesORKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

ORKA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.06%, which is quite impressive.
EPS 1Y (TTM)55.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1360%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ORKA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.13% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5Y14.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORKA Yearly Revenue VS EstimatesORKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
ORKA Yearly EPS VS EstimatesORKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORKA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORKA Price Earnings VS Forward Price EarningsORKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORKA Per share dataORKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 11.77%, ORKA is a good candidate for dividend investing.
The stock price of ORKA dropped by -46.74% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
ORKA's Dividend Yield is rather good when compared to the industry average which is at 10.25. ORKA pays more dividend than 99.65% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.28, ORKA pays a better dividend.
Industry RankSector Rank
Dividend Yield 11.77%

5.2 History

ORKA does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr YearsN/A
Div Non Decr YearsN/A
ORKA Yearly Dividends per shareORKA Yearly Dividends per shareYearly Dividends per share 2024 0.5 1 1.5

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ORKA Yearly Income VS Free CF VS DividendORKA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

More info and screens

ORUKA THERAPEUTICS INC

NASDAQ:ORKA (2/4/2025, 8:00:02 PM)

After market: 14.21 0 (0%)

14.21

+0.51 (+3.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30 2025-01-30
Earnings (Next)N/A N/A
Inst Owners28.43%
Inst Owner Change0.06%
Ins Owners0.2%
Ins Owner Change0%
Market Cap497.35M
Analysts87.69
Price Target44.03 (209.85%)
Short Float %5.78%
Short Ratio5.91
Dividend
Industry RankSector Rank
Dividend Yield 11.77%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 15.27
P/tB 15.27
EV/EBITDA N/A
EPS(TTM)-54.36
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.93
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.27%
ROE -22.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.61
Quick Ratio 26.61
Altman-Z 218.62
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)92.92%
Cap/Depr(5y)95.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1360%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5Y14.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.85%
OCF growth 3YN/A
OCF growth 5YN/A